Evidence map›Paper›PMID 36060945›Full record

ArticleFrontiers in endocrinology2022

Parathyroid hormone alleviates non-alcoholic liver steatosis

Xu Feng, Ye Xiao, Qi Guo, Hui Peng, Hai-Yan Zhou, Jian-Ping Wang, Zhu-Ying Xia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xu FengDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, China.
Ye XiaoDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, China.
Qi GuoDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, China.
Hui PengDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, China.
Hai-Yan ZhouDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, China.
Jian-Ping WangDepartment of Endocrinology, The Second Affiliated Hospital of University of South China, Hengyang, China.
Zhu-Ying XiaDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CNUniversity of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD), hallmarked by liver steatosis, is becoming a global concern, but effective and safe drugs for NAFLD are still lacking at present. Parathyroid hormone (PTH), the only FDA-approved anabolic treatment for osteoporosis, is important in calcium-phosphate homeostasis. However, little is known about its potential therapeutic effects on other diseases. Here, we report that intermittent administration of PTH ameliorated non-alcoholic liver steatosis in diet-induced obese (DIO) mice and db/db mice, as well as fasting-induced hepatic steatosis.

Indexed as

Non-alcoholic Fatty Liver DiseaseParathyroid HormoneAnimalsCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinLipidsLipogenesisMiceMice, ObeseReceptor, Parathyroid Hormone, Type 1CREB1 protein, humanCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinLipidsParathyroid HormonePTH1R protein, humanReceptor, Parathyroid Hormone, Type 1non-alcoholic liver steatosisparathyroid hormonePKA/CREB pathwayPTH1Rtherapeutics

Identifiers

PMID36060945
PMCPMC9428460
OpenAlexW4292255312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.